Ascendis Pharma A/S (NASDAQ:ASND) Shares Gap Up - What's Next?

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $216.56, but opened at $221.89. Ascendis Pharma A/S shares last traded at $215.0240, with a volume of 36,841 shares changing hands.Get Ascendis Pharma A/S alerts:Analysts Set New Price TargetsCan BioMarin Stock Live Up to Wall Street’s High Expectations?Several equities analysts have recently commented on ASND shares. Bank of America boosted their price objective on Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an "overweight" rating in a research note on Thursday, October 9th. Wells Fargo & Company reissued an "overweight" rating and issued a $295.00 price target (up from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Finally, Cowen reiterated a "buy" rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $256.60.Check Out Our Latest Research Report on Ascendis Pharma A/SAscendis Pharma A/S Stock Up 1.8%3 Oversold Stocks with Big RSI Rebound PotentialThe company has a market capitalization of $13.60 billion, a P/E ratio of -42.80 and a beta of 0.44. The business has a 50 day moving average of $202.09 and a 200 day moving average of $185.16. Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The firm had revenue of $290.24 million during the quarter, compared to analyst estimates of $246.91 million. On average, research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year. Hedge Funds Weigh In On Ascendis Pharma A/SA number of institutional investors and hedge funds have recently made changes to their positions in ASND. Perceptive Advisors LLC purchased a new stake in shares of Ascendis Pharma A/S during the 2nd quarter valued at about $166,367,000. Wellington Management Group LLP grew its position in Ascendis Pharma A/S by 95.9% in the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company's stock worth $357,645,000 after acquiring an additional 880,836 shares in the last quarter. Principal Financial Group Inc. increased its stake in Ascendis Pharma A/S by 2,722.9% during the third quarter. Principal Financial Group Inc. now owns 793,677 shares of the biotechnology company's stock worth $157,791,000 after acquiring an additional 765,561 shares during the last quarter. Vestal Point Capital LP raised its position in Ascendis Pharma A/S by 200.0% during the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company's stock valued at $119,286,000 after purchasing an additional 400,000 shares during the period. Finally, Spyglass Capital Management LLC bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $77,267,000. Ascendis Pharma A/S Company Profile (Get Free Report)Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.Recommended StoriesFive stocks we like better than Ascendis Pharma A/SWhat is the Shanghai Stock Exchange Composite Index?Why a 20-Second Flight Test Could Unlock Billions for VerticalHow to Invest in Small Cap Stocks 3 Smart Defensive Stocks for an Uneasy MarketTrading Stocks: RSI and Why it's UsefulThese 3 Stocks Are Using Buybacks to Signal Market ConfidenceThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Ascendis Pharma A/S Right Now?Before you consider Ascendis Pharma A/S, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.While Ascendis Pharma A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here